Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: An economic perspective

Transplant Infectious Disease

Volumn 17, Issue 3, 2015, Pages 334-341

  Kacer, M ^a   Kielberger, L ^a   Bouda, M ^a   Reischig, T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cost; Cytomegalovirus; Economic; Prevention; Renal transplantation; Valacyclovir; Valganciclovir

Indexed keywords

AMPHOTERICIN; BASILIXIMAB; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR; ACICLOVIR; ANTIVIRUS AGENT; VALINE;

ACUTE GRAFT REJECTION; ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG COST; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; ECONOMICS; KIDNEY TRANSPLANTATION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; VALINE;

EID: 84930758262     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12383     Document Type: Article

References (33)

1. Fishman J. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357 (25): 2601-2614.
2. Freeman R. The 'indirect' effects of cytomegalovirus infection. Am J Transplant 2009; 9 (11): 2453-2458.
3. Reischig T, Jindra P, Svecova M, Kormunda S, Opatrny K Jr, Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 2006; 36 (2): 146-151.
4. Sagedal S, Nordal K, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2 (9): 850-856.
5. Reischig T. Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies. Expert Rev Anti Infect Ther 2010; 8 (8): 903-910.
6. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009; 87 (3): 436-444.
7. Smith J, Corey L, Bittner R, et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 2010; 21 (9): 1579-1586.
8. Humar A, Gillingham K, Payne WD, Sutherland DE, Matas AJ. Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 2000; 70 (2): 310-313.
9. Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47 (9): 1550-1556.
10. Stern M, Hirsch H, Cusini A, et al.; Members of Swiss Transplant Cohort Study. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation 2014; 98 (9): 1013-1018.
11. McCarthy JM, Karim MA, Krueger H, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993; 55 (6): 1277-1282.
12. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66 (1): 329-337.
13. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8 (1): 69-77.
14. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96 (4): 333-360.
15. Paya CV. Economic impact of cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001; 3 (Suppl 2): 14-19.
16. Kielberger L, Bouda M, Jindra P, Reischig T. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients. Kidney Blood Press Res 2012; 35 (6): 407-416.
17. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6 (9): 2134-2143.
18. Reischig T, Hribova P, Jindra P, et al. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol 2012; 23 (9): 1588-1597.
19. Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009; 20 (11): 2449-2458.
20. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340 (19): 1462-1470.
21. Legendre C, Beard SM, Crochard A, et al. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. Eur J Health Econ 2005; 6 (2): 172-182.
22. Reischig T, Kacer M, Jindra P, Hes O, Lysak D, Bouda M. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Clin J Am Soc Nephrol 2015; 10 (2): 294-304.
23. IFHP. Comparative Price Report. Variation in Medical and Hospital Prices by Country. International Federation of Health Plans. 2012. Available at www.ifhp.com (accessed March 26, 2013).
24. Gheorghian A, Schnitzler MA, Axelrod DA, Kalsekar A, L'italien G, Lentine KL. The implications of acute rejection and reduced allograft function on health care expenditures in contemporary US kidney transplantation. Transplantation 2012; 94 : 241-249.
25. Luan FL, Kommareddi M, Ojo AO. Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 2011; 11 (9): 1936-1942.
26. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10 (5): 1228-1237.
27. Legendre CM, Norman DJ, Keating MR, Maclaine GD, Grant DM. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation 2000; 70 (10): 1463-1468.
28. Tilden DP, Chapman J, Davey PJ, Solly ML, Crowley S. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. Clin Transplant 2004; 18 (3): 312-320.
29. Lisboa LF, Preiksaitis JK, Humar A, Kumar D. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high risk solid organ transplant recipients. Transplantation 2011; 92 (9): 1063-1068.
30. Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation 2011; 91 (2): 251-255.
31. van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010; 89 (3): 320-326.
32. Reischig T, Prucha M, Sedlackova L, et al. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. Antivir Ther 2011; 16 (8): 1227-1235.
33. Hagenmeyer E-GG, Häussler B, Hempel E, et al. Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications. Transplantation 2004; 77 (10): 1545-1550.